Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
10x Genomics (TXG) had Return on Equity of -1.65% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$150.84M |
|
$-13.47M |
|
$44.66M |
|
$106.18M |
|
$167.89M |
|
$-17.05M |
|
$4.20M |
|
$-12.85M |
|
$-12.85M |
|
$-13.47M |
|
$-13.47M |
|
$-13.47M |
|
$-13.47M |
|
$-17.05M |
|
$-7.09M |
|
128.29M |
|
128.29M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$669.73M |
|
$220.59M |
|
$346.03M |
|
$1.02B |
|
$113.60M |
|
-- |
|
$87.84M |
|
$201.44M |
|
$814.32M |
|
$749.90M |
|
$814.32M |
|
123.13M |
|
| Cash Flow Statement Financials | |
$26.12M |
|
$-1.31M |
|
$-8.42M |
|
$473.97M |
|
$490.29M |
|
$16.32M |
|
$22.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.90 |
|
-- |
|
-- |
|
-- |
|
-- |
|
70.39% |
|
-11.30% |
|
-11.30% |
|
-- |
|
-8.52% |
|
-8.93% |
|
$24.52M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
0.84 |
|
2.69 |
|
33.49 |
|
|
Return on Equity |
-1.65% |
-1.80% |
|
-1.33% |
|
-1.65% |
|
$6.61 |
|
$0.19 |
|
$0.20 |
|